This drug takes the first new approach to schizophrenia treatment in decades," Farchione continued. "This approval offers a ...
The U.S. Food and Drug Administration has approved a new drug for adults with schizophrenia,  the FDA announced Thursday.
Available antipsychotic treatments work by blocking dopamine receptors. The new drug, Cobenfy, takes a different approach.
People with schizophrenia will have a new treatment option for the first time in more than three decades, after the Food and ...
The medication is the first in decades to have a different mode of action than do current drugs, achieving better symptom ...
Cobenfy was approved to reduce the psychotic symptoms associated with schizophrenia. It is a new type of medicine that works ...
Bristol Myers obtained the drug Cobenfy, also known as KarXT, through its $14 billion takeover of Karuna Therapeutics last ...
On STAT's Readout LOUD podcast, Jonathan Wosen talks about Genentech shutting down its cancer immunology team, and the ...
The FDA is set to make a pivotal decision Sept. 26 about KarXT, a novel antipsychotic developed by Karuna Therapeutics. If approved, it would be the first drug with a unique mechanism for treating ...
The FDA has approved KarXT, the first new type of drug for schizophrenia in decades. It appears to be effective, but its main ...
The Food and Drug Administration, as expected, approved KarXT, the first new type of drug for schizophrenia in decades. It appears to be effective, but its main advantage is milder side effects.